دورية أكاديمية
أعرض في EDS

Incidence rates of thrombosis with thrombocytopenia syndrome (TTS) among adults in United States commercial and Medicare claims databases, 2017-2020.

التفاصيل البيبلوغرافية
العنوان: Incidence rates of thrombosis with thrombocytopenia syndrome (TTS) among adults in United States commercial and Medicare claims databases, 2017-2020.
المؤلفون: Lloyd PC; US Food and Drug Administration, Silver Spring, MD, USA. Electronic address: patricia.lloyd@fda.hhs.gov., Lufkin B; Acumen LLC, Burlingame, CA, USA., Moll K; IBM Consulting, Bethesda, MD, USA., Ogilvie RP; Optum Epidemiology, Boston, MA, USA., McMahill-Walraven CN; CVS Health, Blue Bell, PA, USA., Beachler DC; Carelon Research, Wilmington, DE, USA., Kelman JA; Centers for Medicare & Medicaid Services, Baltimore, MD, USA., Shi X; Acumen LLC, Burlingame, CA, USA., Hobbi S; IBM Consulting, Bethesda, MD, USA., Amend KL; Optum Epidemiology, Boston, MA, USA., Djibo DA; CVS Health, Blue Bell, PA, USA., Shangguan S; Acumen LLC, Burlingame, CA, USA., Shoaibi A; US Food and Drug Administration, Silver Spring, MD, USA., Sheng M; IBM Consulting, Bethesda, MD, USA., Secora A; IQVIA, Falls Church, VA, USA., Zhou CK; US Food and Drug Administration, Silver Spring, MD, USA., Kowarski L; IBM Consulting, Bethesda, MD, USA., Chillarige Y; Acumen LLC, Burlingame, CA, USA., Forshee RA; US Food and Drug Administration, Silver Spring, MD, USA., Anderson SA; US Food and Drug Administration, Silver Spring, MD, USA., Muthuri S; IBM Consulting, Bethesda, MD, USA., Seeger JD; Optum Epidemiology, Boston, MA, USA., Kline A; CVS Health, Blue Bell, PA, USA., Reich C; IQVIA, Falls Church, VA, USA., MaCurdy T; Acumen LLC, Burlingame, CA, USA; Department of Economics, Stanford University, Stanford, CA, USA., Wong HL; US Food and Drug Administration, Silver Spring, MD, USA.
المصدر: Vaccine [Vaccine] 2024 Mar 19; Vol. 42 (8), pp. 2004-2010. Date of Electronic Publication: 2024 Feb 22.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Elsevier Science Country of Publication: Netherlands NLM ID: 8406899 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-2518 (Electronic) Linking ISSN: 0264410X NLM ISO Abbreviation: Vaccine Subsets: MEDLINE
أسماء مطبوعة: Publication: Amsterdam, The Netherlands : Elsevier Science
Original Publication: [Guildford, Surrey, UK] : Butterworths, [c1983-
مواضيع طبية MeSH: Thrombocytopenia*/epidemiology , Thrombosis* , COVID-19*/epidemiology, Adult ; Male ; Aged ; Humans ; United States/epidemiology ; Medicare ; Incidence ; COVID-19 Vaccines
مستخلص: Background: Increased risk of thrombosis with thrombocytopenia syndrome (TTS) following adenovirus vector-based COVID-19 vaccinations has been identified in passive surveillance systems. TTS incidence rates (IRs) in the United States (U.S.) are needed to contextualize reports following COVID-19 vaccination.
Methods: We estimated annual and monthly IRs of overall TTS, common site TTS, and unusual site TTS for adults aged 18-64 years in Carelon Research and MarketScan commercial claims (2017-Oct 2020), CVS Health and Optum commercial claims (2019-Oct 2020), and adults aged ≥ 65 years using CMS Medicare claims (2019-Oct 2020); IRs were stratified by age, sex, and race/ethnicity (CMS Medicare).
Results: Across data sources, annual IRs for overall TTS were similar between Jan-Dec 2019 and Jan-Oct 2020. Rates were higher in Medicare (IRs: 370.72 and 365.63 per 100,000 person-years for 2019 and 2020, respectively) than commercial data sources (MarketScan IRs: 24.21 and 24.06 per 100,000 person-years; Optum IRs: 32.60 and 31.29 per 100,000 person-years; Carelon Research IRs: 24.46 and 26.16 per 100,000 person-years; CVS Health IRs: 30.31 and 30.25 per 100,000 person-years). Across years and databases, common site TTS IRs increased with age and were higher among males. Among adults aged ≥ 65 years, the common site TTS IR was highest among non-Hispanic black adults. Annual unusual site TTS IRs ranged between 2.02 and 3.04 (commercial) and 12.49 (Medicare) per 100,000 person-years for Jan-Dec 2019; IRs ranged between 1.53 and 2.67 (commercial) and 11.57 (Medicare) per 100,000 person-years for Jan-Oct 2020. Unusual site TTS IRs were higher in males and increased with age in commercial data sources; among adults aged ≥ 65 years, IRs decreased with age and were highest among non-Hispanic American Indian/Alaska native adults.
Conclusion: TTS IRs were generally similar across years, higher for males, and increased with age. These rates may contribute to surveillance of post-vaccination TTS.
Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: KM is an employee of Regeneron Pharmaceuticals. RPO, KA, and JS are employees of Optum and may own stock in UnitedHealth Group. CKZ was employed by the FDA when actively contributing to the study. Currently, CKZis an employee of Moderna Inc and may own stock;CKZ also discloses previous employment (subsequent to study contributions) with Pfizer Inc.
(Published by Elsevier Ltd.)
فهرسة مساهمة: Keywords: Background rates; COVID-19 vaccine; Thrombosis with thrombocytopenia syndrome (TTS)
المشرفين على المادة: 0 (COVID-19 Vaccines)
تواريخ الأحداث: Date Created: 20240222 Date Completed: 20240318 Latest Revision: 20240318
رمز التحديث: 20240318
DOI: 10.1016/j.vaccine.2024.02.017
PMID: 38388240
قاعدة البيانات: MEDLINE
الوصف
تدمد:1873-2518
DOI:10.1016/j.vaccine.2024.02.017